Skip to main content

Table 1 Baseline demographic and clinical characteristics of subjects who maintained the eradicated state by quadruple therapy (EBMT) or moxifloxacin-based triple therapy (MEA)

From: Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

Variable category Total EBMT MEA p-value*
  (N = 175) (N = 59) (N = 116)  
Gender (N = 175) (n = 59) (n = 116)  
  Male (104, 59.4%) (35, 59.3%) (69, 59.5%) 0.98
  Female (71, 40.6%) (24, 40.7%) (47, 40.5%)  
Age (years) (mean ± SD) (N = 175) (n = 59) (n = 116) 0.67
(56.6 ± 9.4) (56.1 ± 9.3) (56.8 ± 9.5)
Clinical diagnosis (N = 175) (n = 59) (n = 116)  
  Early gastric cancer (40, 22.9%) (11, 18.6%) (29, 25.0%) 0.06
  Dysplasia (19, 10.9%) (3, 5.1%) (16, 13.8%)  
  Peptic ulcer disease (34, 19.4%) (17, 28.8%) (17, 14.7%)  
  Chronic gastritis (82, 46.9%) (28, 47.5%) (54, 46.6%)  
Histological AG in either antrum or body (N = 116) (n = 37) (n = 79)  
  Yes (67, 57.8%) (21, 56.8%) (46, 68.7%) 0.88
  No (49, 42.2%) (16, 43.2%) (33, 41.8%)  
Histological IM in either antrum or body (N = 144) (n = 47) (n = 97)  
  Yes (84, 58.3%) (23, 48.9%) (61, 62.9%) 0.11
  No (60, 41.7%) (24, 51.1%) (36, 37.1%)  
  1. EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atrophic gastritis, IM, intestinal metaplasia.
  2. All of early gastric cancer patients were cured by endoscopic submucosal dissection.
  3. *p-value for Pearson chi-square test for comparison of categorical data, and independent samples t-test for comparison of age.